SMOT
VanEck Morningstar SMID Moat ETF
SMOT tracks an index made up of two equally-weighted sub-portfolios, comprised of small- and mid-cap companies believed to have durable competitive advantages and attractive valuations.
US
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 339.8 M
ASSETS UNDER MGMT
49 bp
EXPENSES
Fund Basics
| Inception date | Oct 04, 2022 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| BIO-TECHNE CORPORATION | 1.7 % |
| ACUITY BRANDS INC | 1.6 % |
| MASCO CORP | 1.5 % |
| BLOCK INC. | 1.4 % |
| ROYALTY PHARMA PLC CLASS A | 1.4 % |
| BIOGEN IDEC INC | 1.4 % |
| GENTEX CORP | 1.4 % |
| IONIS PHARMACEUTICALS, INC. | 1.4 % |
| CARNIVAL CORP | 1.4 % |
| BROWN-FORMAN CORP-CLASS B | 1.4 % |
Constituent Breakdown
| Number of holdings | 112 |
| Herfindahl-Hirschman Index | 106 |
| Wgt avg mkt cap (mns) | $25,143 |
| Large cap (>$10bn) | 82.5% |
| Mid cap ($2-10bn) | 17.5% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 100.0% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 92.7 % |
 |
BRITAIN | 3.2 % |
 |
NETHERLANDS | 0.8 % |
 |
IRELAND | 0.7 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 7.3% | 11.7% | 10.3% | 9.1% | -- | -- | -- | 11.7% |
| Dividend Yield | 0.0% | 1.5% | 1.4% | 1.2% | -- | -- | -- | 1.0% |
| Total Returns | 7.3% | 13.2% | 11.7% | 10.2% | -- | -- | -- | 12.8% | Ann. Volatility | 14.5% | 14.3% | 18.5% | 17.4% | -- | -- | -- | 18.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.82 | 51% |
| MSCI EAFE | 0.61 | 45% |
| MSCI Emg Mkts | 0.33 | 29% |
Liquidity Measures
| Avg. volume (000) | 25 |
| ADV traded (mns) | $1 |
| Turnover | 0.3% |
| Avg. Bid/Ask (% of price) | 0.12% |
Technical Indicators
| 30d moving avg. (EMA) | $38.39 |
| Relative strength (RSI) | 61 |
| MACD/Signal | 0.34/0.29 |
| Bollinger Bands (Upper/Lower) | $39.48/$37.75 |
| Short interest (% of AUM) | 0.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. SMOT |
Expenses vs. SMOT |
ALTAR Score™ vs. SMOT |
|---|---|---|---|---|
| MOAT | VanEck Morningstar Wide Moat ETF | 22.8% | -3 bp | -1.1% |
| IMCV | iShares Morningstar Mid-Cap Value ETF | 20.7% | -43 bp | +0.5% |
| MVAL | VanEck Morningstar Wide Moat Value ETF | 19.4% | 0 bp | -0.4% |
| VO | Vanguard Mid-Cap ETF | 18.5% | -45 bp | -1.1% |
| IMCB | iShares Morningstar Mid-Cap ETF | 18.1% | -45 bp | -1.3% |
| VOE | Vanguard Mid-Cap Value ETF | 17.8% | -42 bp | +0.4% |
| MOTG | VanEck Morningstar Global Wide Moat ETF | 17.0% | +3 bp | +2.1% |
| RSPE | Invesco ESG S&P 500 Equal Weight ETF | 16.1% | -29 bp | -1.2% |
| ONEY | State Street SPDR Russell 1000 Yield Focus ETF | 15.5% | -29 bp | +1.6% |
| COWZ | Pacer US Cash Cows 100 ETF | 15.4% | 0 bp | +2.6% |
Risk and Returns: SMOT vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/5/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
7.0%
ALTAR SCORE™
79th
PERCENTILE
OVERWEIGHT
ETFRC RATING
There are 1,395 funds in the US Equity category with an average
ALTAR Score™ of 5.3% and a standard deviation
of 2.1%. SMOT's ALTAR Score™ is approximately 0.8 standard
deviations above the category average. This places SMOT in the 79th percentile
among funds in the category.
Sell-Side Consensus
$45.2
PRICE TARGET
+14.4%
UPSIDE